Implications of Therapy Choice on Overall Survival in Metastatic Renal Cell Carcinoma: A Single Institution Experience
- 1 January 2005
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 22 (4) , 399-406
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Prognostic Factors in Patients with Advanced Renal Cell CarcinomaClinical Cancer Research, 2004
- Using Protein Expressions to Predict Survival in Clear Cell Renal CarcinomaClinical Cancer Research, 2004
- A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancerEuropean Journal of Cancer, 2004
- Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)Journal of Clinical Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative GroupJournal of Clinical Oncology, 2003
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinomaCancer, 2002
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998